StockNews.AI
SION
StockNews.AI
190 days

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

1. Sionna Therapeutics raised $219.2 million in IPO, selling 12.2 million shares. 2. Shares priced at $18.00 and began trading on Nasdaq under 'SION'. 3. Company focused on CFTR protein for cystic fibrosis treatment innovation. 4. Pipeline includes molecules correcting F508del mutation defects. 5. Novel medicines may improve clinical outcomes for cystic fibrosis patients.

6m saved
Insight
Article

FAQ

Why Bullish?

Successful IPO indicates strong market interest, potentially increasing shareholder confidence. Past biotech IPOs often see initial price increases due to investor enthusiasm.

How important is it?

The IPO signifies financial health and market confidence in Sionna's future. Major funding enhances the ability to develop innovative cystic fibrosis treatments.

Why Short Term?

Initial market excitement from IPO can lead to price surge. However, sustained impact depends on clinical progress and product pipeline developments.

Related Companies

CFTRVRTXABBV
February 10, 2025 16:03 ET  | Source: Sionna Therapeutics, Inc. BOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the closing of its upsized initial public offering of 12,176,467 shares of its common stock at a public offering price of $18.00 per share, which includes 1,588,234 shares issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock in the offering. All of the shares of common stock were sold by Sionna. The gross proceeds to Sionna from the initial public offering were, including full exercise of the underwriters’ option to purchase additional shares, approximately $219.2 million, before deducting underwriting discounts and commissions and offering expenses. The shares commenced trading on the Nasdaq Global Market on February 7, 2025 under the ticker symbol “SION.” Goldman Sachs & Co. LLC, TD Cowen, Stifel, and Guggenheim Securities acted as joint book-running managers for the offering. A registration statement relating to the shares sold in the initial public offering has been filed with the Securities and Exchange Commission and was declared effective by on February 6, 2025. This offering was made only by means of a prospectus. A copy of the final prospectus may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: (866) 471-2526, via fax: 212 902-9316, or via email: prospectus-ny@ny.email.gs.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (855) 495-9846, or by email at TD.ECM_Prospectus@tdsecurities.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Sionna TherapeuticsSionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for CF by developing novel medicines that normalize the function of the CFTR protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (NBD1), which the company believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, the company is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Media ContactAdam DaleyCG Life212.253.8881adaley@cglife.com Investor ContactJuliet Labadorfir@sionnatx.com

Related News